Adherence to Dyslipidemia Therapy: Harnessing Evidence From Randomized Evaluations in AtheroSclerotic CardioVascular Disease
NCT07522645 · Status: NOT_YET_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 22000
Last updated 2026-04-15
Summary
The goal of the ADHERE-ASCVD study is to evaluate and optimize patient-facing messaging strategies to improve statin refill and adherence among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes.
The main questions it aims to answer are:
1. Do different outreach methods (such as text messages, secure portal messages, or email) increase short-term statin refill compared to usual care?
2. Among patients who do not initially refill their prescription, does changing the outreach method improve refill rates?
The team with operational partners will evaluate the comparitive effectivessness of multiple messaging strategies delivered through existing health system communication channels, including SMS (text messaging), secure patient portal messages, non-secure email, and usual care (no additional outreach).
Participants
* Receive an initial outreach message encouraging statin refill (or usual care) Be monitored for statin refill within 14 days
* Potentially receive a second outreach message using the same or a different communication method if they do not initially refill their prescription
* Have their medication refill patterns tracked over time, including longer-term adherence outcomes
Conditions
Interventions
- BEHAVIORAL
-
SMS (Initial Outreach)
Participants will receive an initial SMS (text message) encouraging statin refill. Messages may include reminder prompts and interactive features implemented through automated keyword-triggered responses that provide refill instructions or educational information.
- BEHAVIORAL
-
Secure Portal Message (Initial Outreach)
Participants will receive an initial secure message through the kp.org patient portal encouraging statin refill. Messages are delivered within the secure portal environment and may include informational and reminder content.
- BEHAVIORAL
-
Non-secure Email (Initial Outreach)
Participants will receive an initial non-secure email encouraging statin refill. Emails may include informational content and reminders but are delivered outside of the secure patient portal.
- BEHAVIORAL
-
SMS (Follow-up for Non-responders)
Participants who do not refill their prescription within 14 days of the initial outreach will receive a follow-up SMS (text message) encouraging statin refill. Messages may include reminder prompts and interactive features implemented through automated keyword-triggered responses that provide refill instructions or educational information.
- BEHAVIORAL
-
Secure Portal Message (Follow-up for Non-responders)
Participants who do not refill their prescription within 14 days of the initial outreach will receive a follow-up secure portal message through the kp.org patient portal encouraging statin refill. Messages are delivered within the secure portal environment and may include informational and reminder content.
- BEHAVIORAL
-
Non-secure Email (Follow-up for Non-responders)
Participants who do not refill their prescription within 14 days of the initial outreach will receive a follow-up non-secure email encouraging statin refill. Emails may include informational content and reminders but are delivered outside of the secure patient portal.
Sponsors & Collaborators
- lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- OTHER
- Masking
- TRIPLE
- Model
- SEQUENTIAL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2026-04-14
- Primary Completion
- 2026-05-30
- Completion
- 2028-12-31
Countries
- United States
Study Locations
More Related Trials
-
Barriers to Optimal LDL-C Targets in Patients With Atherosclerotic Cardiovascular Disease
NCT06897566 ·Status: COMPLETED
-
ACHIEVE Pilot Statins for Vascular Protection
NCT06551701 ·Status: ACTIVE_NOT_RECRUITING
-
Statin Reminders for Improving Prescribing in Primary Care
NCT06456658 ·Status: COMPLETED ·Phase: NA
-
Low-Density Lipoprotein Cholesterol-targeting Statin Therapy Versus the Intensity-based Statin Therapy in Patients With Coronary Artery Disease
NCT02579499 ·Status: UNKNOWN ·Phase: PHASE4
-
Habit Formation for Adherence to Statin Use and LDL Reduction
NCT01798784 ·Status: COMPLETED ·Phase: NA
-
Effectiveness of a Combined Strategy to Improve Therapeutic Compliance and Degree of Control Among Patients With Hypercholesterolaemia
NCT02314663 ·Status: UNKNOWN ·Phase: NA
-
The HDL Particle Protection Study
NCT02125682 ·Status: COMPLETED ·Phase: PHASE4
-
Effect of a Decision Aid About Statin Use in Patients With Type 2 Diabetes Mellitus
NCT00217061 ·Status: COMPLETED ·Phase: PHASE3
-
Patient-engaged Development and Testing of Educational Content on Side Effects of Statins
NCT07094412 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Improving Lipid Optimization Quality and Treatment Options in ASCVD
NCT06960655 ·Status: ENROLLING_BY_INVITATION ·Phase: NA
-
Study to Assess the Tolerability and Efficacy of Anacetrapib in Patients With Coronary Heart Disease (CHD) or CHD Risk-Equivalent Disease (MK-0859-019)
NCT00685776 ·Status: COMPLETED ·Phase: PHASE3
-
Notify 2: An Evaluation of the Impact of Notification of Incidental Coronary Artery Calcium on Statin Rates
NCT05394181 ·Status: WITHDRAWN ·Phase: NA
-
A Study to Determine the Degree of Additional Reduction in CV Risk in Lowering LDL Below Minimum Target Levels
NCT00327691 ·Status: COMPLETED ·Phase: PHASE4
-
A Multiple Ascending Dose Study of HTD1801 in Adults With Hypercholesterolemia
NCT03381287 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Adherence and Persistence to Inclisiran Among Early Users in Germany
NCT05870657 ·Status: COMPLETED
-
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)
NCT02585778 ·Status: COMPLETED ·Phase: PHASE3
-
Implementation of an Algorithm- and Multi-professional Team-supported Strategy to Improve Lipid Management of Patients With Atherosclerotic Cardiovascular Disease
NCT07334834 ·Status: RECRUITING ·Phase: NA
-
A Study of AZD8233 in Participants With Dyslipidemia
NCT04641299 ·Status: COMPLETED ·Phase: PHASE2
-
Percentage of Secondary Prevention Patients Treated to Their LDL-C Targets
NCT00536965 ·Status: COMPLETED
-
Moderate-intensity Statin vs. Individualized LDL-C Target-based Therapy in Older Adults With Type 2 Diabetes (iTARGET-Elderly Study)
NCT07359105 ·Status: RECRUITING ·Phase: NA
-
To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 20 mg (0653-079)(COMPLETED)
NCT00276458 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Efficacy and Safety of Co-administration of AD-2281 and AD-2282
NCT06747936 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Patient Autonomy and Statin Therapy Adherence
NCT05845580 ·Status: COMPLETED ·Phase: NA
-
A Study to Assess the Safety, Efficacy and Tolerability of AZD8233 Treatment in Participants With Hyperlipidaemia
NCT04964557 ·Status: COMPLETED ·Phase: PHASE2
-
Atorvastatin and Endothelial Function in Type 2 Diabetes Mellitus (ATTEND-Study)
NCT00124397 ·Status: COMPLETED ·Phase: PHASE4